Back to Search Start Over

Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.

Authors :
Pinheiro M
Peixoto A
Santos C
Escudeiro C
Bizarro S
Pinto P
Santos R
Pinto C
Guerra J
Silva J
Teixeira MR
Source :
Cancer genetics [Cancer Genet] 2020 Oct; Vol. 248-249, pp. 18-24. Date of Electronic Publication: 2020 Sep 11.
Publication Year :
2020

Abstract

The genomic consequence and clinical interpretation of large duplications are difficult to infer without determining the location and orientation of the duplicated sequence. We aimed to characterize two intragenic duplications detected in two hereditary breast and ovarian cancer syndrome (HBOC) families, namely BRCA1 exon 4 to 6 and BRCA2 exon 17 to 18, previously detected by multiplex ligation probe amplification and initially classified as variants of unknown significance. Using long range PCR, with duplication-specific primers, we were able to ascertain the genomic breakpoints and observed that the two rearrangements occurred in tandem and in direct orientation. The BRCA1 c.134+440_441+870dup and BRCA2 c.7806-2083_8332-1512dup duplications here identified are predicted to cause frameshifts that create a premature stop codon and were reclassified as pathogenic. Furthermore, both families present phenotypic traits typical of HBOC syndrome. We also observed that the genomic breakpoints of these two duplications occurred within highly homologous Alu elements. Concluding, we characterized two in tandem BRCA1 and BRCA2 duplications that likely occurred by Alu-mediated homologous recombination, allowing identification of the underlying cause of the HBOC syndrome in these families.<br />Competing Interests: Declaration of Competing Interest None.<br /> (Copyright © 2020. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
2210-7762
Volume :
248-249
Database :
MEDLINE
Journal :
Cancer genetics
Publication Type :
Academic Journal
Accession number :
32971473
Full Text :
https://doi.org/10.1016/j.cancergen.2020.09.001